Rapid tests for sexually transmitted infections (STIs): the way forward

Peeling, Rosanna W.; Holmes, King K.; Mabey, David; Ronald, Allan

doi:10.1136/sti.2006.024265

Cited by 507 publications

(380 citation statements)

References 39 publications

Supporting

Mentioning

363

Contrasting

Unclassified

Order By: Relevance

“…The World Health Organization Sexually Transmitted Diseases Diagnostics Initiative has developed the ASSURED (affordable, sensitive, specific, user-friendly, rapid and robust, equipment-free, and deliverable to those in need) criteria as benchmarks to determine whether a diagnostic test addresses certain disease control needs (46). According to a qualitative study of focus group discussions with medical care providers, C. trachomatis was identified as the priority organism for the development of a new POC test and the ideal POC test for C. trachomatis detection should be accurate and rapid (Ͻ20 min) (47).…”

Section: Discussionmentioning

confidence: 99%

Blind Evaluation of the Microwave-Accelerated Metal-Enhanced Fluorescence Ultrarapid and Sensitive Chlamydia trachomatis Test by Use of Clinical Samples

et al. 2013

View full text Add to dashboard Cite

Accurate point-of-care (POC) diagnostic tests for Chlamydia trachomatis infection are urgently needed for the rapid treatment of patients. In a blind comparative study, we evaluated microwave-accelerated metal-enhanced fluorescence (MAMEF) assays for ultrafast and sensitive detection of C. trachomatis DNA from vaginal swabs. The results of two distinct MAMEF assays were compared to those of nucleic acid amplification tests (NAATs). The first assay targeted the C. trachomatis 16S rRNA gene, and the second assay targeted the C. trachomatis cryptic plasmid. Using pure C. trachomatis, the MAMEF assays detected as few as 10 inclusion-forming units/ml of C. trachomatis in less than 9 min, including DNA extraction and detection. A total of 257 dry vaginal swabs from 245 female adolescents aged 14 to 22 years were analyzed. Swabs were eluted with water, the solutions were lysed to release and to fragment genomic DNA, and MAMEF-based DNA detection was performed. The prevalence of C. trachomatis by NAATs was 17.5%. Of the 45 samples that were C. trachomatis positive and the 212 samples that were C. trachomatis negative by NAATs, 33/45 and 197/212 were correctly identified by the MAMEF assays if both assays were required to be positive (sensitivity, 73.3%; specificity, 92.9%). Using the plasmid-based assay alone, 37/45 C. trachomatis-positive and 197/212 C. trachomatis-negative samples were detected (sensitivity, 82.2%; specificity, 92.9%). Using the 16S rRNA assay alone, 34/45 C. trachomatis-positive and 197/212 C. trachomatis-negative samples were detected (sensitivity, 75.5%; specificity, 92.9%). The overall rates of agreement with NAAT results for the individual 16S rRNA and cryptic plasmid assays were 89.5% and 91.0%, respectively. Given the sensitivity, specificity, and rapid detection of the plasmid-based assay, the plasmid-based MAMEF assay appears to be suited for clinical POC testing.

show abstract

Section: Discussionmentioning

confidence: 99%

Blind Evaluation of the Microwave-Accelerated Metal-Enhanced Fluorescence Ultrarapid and Sensitive Chlamydia trachomatis Test by Use of Clinical Samples

et al. 2013

View full text Add to dashboard Cite

show abstract

“…These eventually received US FDA emergency use authorization (EUA; EZ1 assay) or were made commercially available under the selfcertification CE marking principles (Altona RealStar Ò Filovirus Screen) [11] Molecular diagnostics for infectious diseases at the point of need Following 9/11 and the subsequent airborne viral disease pandemics, efforts were made to develop decentralized, point-ofcare NATs [12]. The resulting solutions, however, were not designed with resource-limited settings in mind [13], despite the ASSURED criteria espoused by the WHO [14]. Thus, the need for a safe, cheap, simple, robust, portable and battery-operated solution remained, presenting an attractive development opportunity for emerging NAT technologies.…”

Section: Background: Clinical Diagnosis Of Ebolavirus Diseasementioning

confidence: 99%

Introducing EbolaCheck: potential for point-of-need infectious disease diagnosis

Moschos

2015

Expert Review of Molecular Diagnostics

View full text Add to dashboard Cite

“…As per the World Health Organization diagnosis should be ASSURED: Affordable, Sensitive, Specific, User friendly, Rapid and robust, Equipment free and Delivery to end users [25]. Point care of testing, microfluidic paper based analytical devices is rapid, less expensive, and more multiplexed than the instrumental analysis.…”

Section: Glucose Monitoring Methods: Invasive and Non-invasivementioning

confidence: 99%

Role of Peroxidase in Clinical Assays: A Short Review

Shivakumar¹,

Bg²,

Mr³

2017

J Clin Nutr Diet

View full text Add to dashboard Cite

Development of sensitive enzymatic methods for hydrogen peroxide is key for the quantification of several bioconstituents such as glucose, triglycerides, creatinine, and uric acid and so on. Hydrogen peroxide released by the oxidase enzymes are quantified by peroxidase enzyme involving spectrophotometry, fluorimetry, chemiluminisence, potentiometric sensing, amperometric, coulometric and such others. Authors in this line, present a short review on the assay of peroxidase. The entire review is divided into three different sections; first the importance of peroxidase clinically, secondly peroxidase chemistry with hydrogen peroxide and finally its role in the assay of bioconstituents.Keywords: Peroxidase; Clinical importance; Oxidase enzymes; Glucose assay; Nano sensors Role of Peroxidase in ClinicalAssays: A Short Review Peroxidase: A Clinically Important EnzymePeroxidases are widely distributed in nature especially in animal and plant cells. Peroxidases comprise of three major categories; plant peroxidases, animal peroxidases and catalases. These enzymes utilize hydrogen peroxide to catalyze the oxidation of variety of organic and inorganic compounds.

show abstract

Rapid tests for sexually transmitted infections (STIs): the way forward

Cited by 507 publications

References 39 publications

Blind Evaluation of the Microwave-Accelerated Metal-Enhanced Fluorescence Ultrarapid and Sensitive Chlamydia trachomatis Test by Use of Clinical Samples

Blind Evaluation of the Microwave-Accelerated Metal-Enhanced Fluorescence Ultrarapid and Sensitive Chlamydia trachomatis Test by Use of Clinical Samples

Introducing EbolaCheck: potential for point-of-need infectious disease diagnosis

Role of Peroxidase in Clinical Assays: A Short Review

Contact Info

Product

Resources

About